Inhibikase Therapeutics, Inc. Common Stock (IKT)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Inhibikase Therapeutics, Inc. Common Stock (IKT) is listed on Nasdaq, where it has traded since December 23, 2020.
- Listed On
- Nasdaq
- Listed Since
- December 23, 2020
- Employees
- 35
- Market Cap
- $226M
About Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 103 institutions reported holding IKT, with 117.9 million shares worth $239.2 million in aggregate. The largest reported holder was Sands Capital Ventures, with 13.0 million shares worth $26.4 million. Of the 5 largest holders listed below, 2 added shares and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Sands Capital Ventures | 13,018,965 | $26M | Unchanged |
| Soleus Capital Management | 10,875,000 | $22M | Unchanged |
| Trails Edge Capital Partners | 9,051,318 | $18M | Added 12.34% |
| Fairmount Funds Management | 8,625,000 | $18M | Unchanged |
| BlackRock | 7,768,057 | $16M | Added 23.24% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is IKT?
Inhibikase Therapeutics, Inc. Common Stock (IKT) is listed on Nasdaq, where it has traded since December 23, 2020.
Who are the largest institutional holders of IKT?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of IKT were Sands Capital Ventures, Soleus Capital Management and Trails Edge Capital Partners.
How many institutions own IKT?
103 institutions reported a position in IKT for the quarter ended June 30, 2026, worth $239.2 million in total.
Did institutions buy or sell IKT last quarter?
Of the 5 largest reported holders, 2 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for IKT.
Every reported institutional holder, plus insider and congressional trades in IKT, on SentiSense.